Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Sep 17, 2026
TickeronGET DAILY SIGNALS
Tempus AI (TEM) Rallies +35.5% in 30 Days: Short Squeeze and Merck Tie-Up Fuel the Move

Tempus AI (TEM) Rallies +35.5% in 30 Days: Short Squeeze and Merck Tie-Up Fuel the Move

Key Takeaways

  • Tempus AI (TEM) climbed roughly 35.5% over the trailing 30 days, from about $51.64 to $69.97 on a closing basis.
  • The advance was amplified by a technical short squeeze tied to positive third-party precision-medicine news and an expanded AI collaboration with Merck.
  • Over the last quarter, TEM has risen approximately 37.6%, recovering sharply after touching a 52-week low near $40.77 in late July.
  • Second-quarter 2026 revenue grew 22% year over year, led by the Diagnostics and Data & Apps segments.
  • Analyst consensus on TEM remains a Buy, though the stock now trades near or above the average 12-month price target.

Tempus AI's Business and Market Standing

Tempus AI, Inc. is a healthcare technology company that applies artificial intelligence and machine learning to precision medicine. Founded in 2015 and headquartered in Chicago, the company operates a closed-loop platform that connects laboratory diagnostics, an analytics engine, and a repository of multimodal clinical and molecular data. Its offerings span genomic and molecular diagnostics, the Hub clinical application for physicians, the Lens software platform for life sciences research, and data-licensing products under the Insights brand, with applications across oncology, cardiology, neuropsychiatry, radiology, and infectious disease.

Tempus went public on the Nasdaq in June 2024, and investors follow the stock closely because of its rapid revenue growth, its expanding data moat, and a pipeline of AI-enabled diagnostic tools and pharmaceutical collaborations. Strategic relationships include partnerships with major life-sciences and pharmaceutical companies, reinforcing its position at the intersection of healthcare data and AI. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

TEM's Price Moves: 30-Day Surge and Quarterly Recovery

Over the trailing 30 days, TEM has advanced approximately 35.5%, moving from a closing price near $51.64 to $69.97. The move was not linear: shares surged sharply in mid-August, pulled back in late August and early September, and then regained momentum into mid-September.

The broader quarterly trend tells a similar story of volatility followed by recovery. Roughly three months earlier, shares traded near $50.84. After sliding to a 52-week low around $40.77 in late July, the stock reversed powerfully, ultimately gaining about 37.6% over the full quarter. This "V-shaped" pattern reflects both a period of selling pressure and a rapid re-rating driven by catalysts discussed below.

Key Drivers Behind the Recent 30-Day Advance

The most dramatic catalyst came in mid-August, when a third-party clinical breakthrough in cancer-vaccine research triggered a broad rally across precision-medicine names. Tempus, which provides genomic testing and data infrastructure relevant to personalized oncology, was a notable beneficiary, and heavy short interest amplified the move into a technical short squeeze that lifted shares sharply over several sessions.

Around the same period, Tempus expanded its AI-driven precision-medicine partnership with Merck (MRK), reinforcing investor confidence in its pharmaceutical collaboration pipeline. The company also received FDA 510(k) clearance for Tempus ECG-PH, an AI-enabled software device that detects signs of pulmonary hypertension from standard 12-lead electrocardiograms, and announced up to $9.5 million in ARPA-H funding to deploy autonomous AI in cardiology.

Analyst activity added further support. Personalis (PSNL) acquisition prospects prompted upgrades and price-target increases, including an Overweight initiation from Cantor Fitzgerald and an upgrade to Overweight from Piper Sandler, alongside higher targets from H.C. Wainwright. Together, these developments lifted sentiment and drove the stock's 30-day advance.

Factors Shaping Performance Over the Quarter

The quarter's trajectory was shaped first by a drawdown and then by a decisive reversal. Through late July, shares came under pressure, dipping to a 52-week low near $40.77 as growth-oriented healthcare names faced broad selling. The turning point arrived with second-quarter earnings, when Tempus reported 22% year-over-year revenue growth led by its Diagnostics and Data & Apps businesses, reinforcing the company's ability to scale despite ongoing net losses.

From there, the narrative shifted toward expansion. The pending Personalis acquisition, new FDA clearances, the Merck collaboration, and a steady stream of analyst initiations and upgrades underpinned a multi-month re-rating. The result was a quarter defined by a sharp recovery and renewed investor interest in Tempus as a leading AI-enabled precision-medicine platform.

What Could Influence TEM Next

Looking ahead, several factors could influence TEM's trajectory. Quarterly earnings remain the primary event, with the next report expected in early November 2026; investors will watch revenue growth, margins, and guidance for the Diagnostics and Data & Apps segments. Progress on the pending Personalis acquisition, including regulatory and shareholder approvals, is another key milestone.

Broader catalysts include further FDA clearances for AI-enabled diagnostic devices, new or expanded pharmaceutical and data-licensing partnerships, and developments in the competitive precision-medicine landscape. Macroeconomic conditions, interest-rate expectations, and sentiment toward high-growth, higher-beta healthcare technology names will also matter, given TEM's historically elevated volatility. As always, these are factors to monitor rather than predictions of future performance. From what I see, I’m watching this closely as the next earnings cycle approaches.

Tracking Automated Strategies with Tickeron

One resource I turn to when evaluating data-driven approaches for names like this is Tickeron’s Trending AI Robots. The page highlights a selection of AI trading bots that monitor thousands of tickers, focusing on those showing strong recent performance across different strategies and timeframes. It offers a practical way to compare automated options without sifting through every available bot.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TEM

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


TEM in downward trend: price dove below 50-day moving average on November 13, 2026

TEM moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend. In 19 of 20 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TEM as a result. In 30 of 37 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for TEM turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 23 similar instances when the indicator turned negative. In 17 of the 23 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

The 10-day moving average for TEM crossed bearishly below the 50-day moving average on November 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for TEM entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for TEM's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +19.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEM advanced for three days, in 117 of 132 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

TEM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TEM's P/B Ratio (31.032) is slightly higher than the industry average of (4.523). TEM has a moderately low P/E Ratio (-52.812) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (8.696) is also within normal values, averaging (6.105).

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. TEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -13%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 2%. DRIO experienced the highest price growth at 5%, while LFMD experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 27%. For the same stocks of the Industry, the average monthly volume growth was 34% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -5 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Industry
N/A
Address
600 West Chicago Avenue
Phone
+1 800 976-5448
Employees
3800
Web
https://www.tempus.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.